Marinus Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Marinus Pharmaceuticals

08/11/2022 14:31

* Marinus Pharmaceuticals Inc  MRNS.OQ  reported a quarterly
adjusted loss of 94 cents​​ per share for the quarter ended in
September. The mean expectation of nine analysts for the quarter
was for earnings of 47 cents per share.
    * Revenue fell 76.9% to $2.34 million from a year ago;
analysts
expected $29.48 million. 
    * Marinus Pharmaceuticals Inc's reported EPS for the quarter
was
$1.89​.
    * The mean earnings estimate of analysts had risen by
about 189.8%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Marinus Pharmaceuticals Inc shares had fallen by 15.6%
this
quarter and lost 52.8% so far this year.
    * The company reported quarterly net income of $71.63
million.
    * Wall Street's median 12-month price target for Marinus
Pharmaceuticals Inc is $28.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
8 at 02:31 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      0.47           -0.94          Missed
 Jun. 30 2022      -0.69          -1.06          Missed
 Mar. 31 2022      -0.85          -0.52          Beat
 Dec. 31 2021      -0.76          -0.77          Missed